Radius Health continues fall following phase 3 osteoporosis trial miss; shares off 44%

Nattakorn Maneerat/iStock via Getty Images

• Shares of Radius Health (RDUS -44.9%) have continued to fall in afternoon trading after the company this morning said a late-stage trial of its abaloparatide transdermal system missed its primary endpoint.
• The trial was designed to show non-inferiority between Abalo-TDS and Tymlos (abaloparatide subcutaneous injection).
• Radius plans to submit an sNDA for Tymlos for osteoporosis in men in 2022.